Is INCY stock overvalued right now?

Based on our discounted cash flow and relative valuation models, INCY appears to trade above fair value by approximately 18.6%. This suggests the market may be pricing in elevated growth expectations or sentiment premiums.

What is INCY fair value based on current fundamentals?

Our fair value estimate for INCY is $99.15, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

How risky is INCY compared with other stocks?

INCY carries a beta of 0.77 suggests a defensive profile. Investors should weigh macro exposure against their own risk tolerance.

Is INCY still growing?

Latest trailing metrics show revenue growth of 37.7% and earnings growth of 37.7%. Profit margins are 27.7%.

What do analysts think about INCY?

Analyst consensus target is $127.74, implying 4.9% upside. The street recommendation is "buy".

What could change the investment case for INCY?

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

HealthcareUpdated·Data: Yahoo Finance, SEC EDGAR·Data delayed ~5 min

Insight INCY 100% YoY Growth ESG Rating result Momentum

NMS · Healthcare · Biotechnology

$121.74

-0.45 (-0.37%)

Stock valuation guide Macro risk explained guide

About the Author

Phasakorn Traklang (Peach) — Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.